Your browser doesn't support javascript.
Vaccine Candidate Against COVID-19 Based on Structurally Modified Plant Virus as an Adjuvant.
Kovalenko, Angelina O; Ryabchevskaya, Ekaterina M; Evtushenko, Ekaterina A; Manukhova, Tatiana I; Kondakova, Olga A; Ivanov, Peter A; Arkhipenko, Marina V; Gushchin, Vladimir A; Nikitin, Nikolai A; Karpova, Olga V.
  • Kovalenko AO; Department of Virology, Faculty of Biology, Lomonosov Moscow State University, Moscow, Russia.
  • Ryabchevskaya EM; Department of Virology, Faculty of Biology, Lomonosov Moscow State University, Moscow, Russia.
  • Evtushenko EA; Department of Virology, Faculty of Biology, Lomonosov Moscow State University, Moscow, Russia.
  • Manukhova TI; Department of Virology, Faculty of Biology, Lomonosov Moscow State University, Moscow, Russia.
  • Kondakova OA; Department of Virology, Faculty of Biology, Lomonosov Moscow State University, Moscow, Russia.
  • Ivanov PA; Department of Virology, Faculty of Biology, Lomonosov Moscow State University, Moscow, Russia.
  • Arkhipenko MV; Department of Virology, Faculty of Biology, Lomonosov Moscow State University, Moscow, Russia.
  • Gushchin VA; Department of Virology, Faculty of Biology, Lomonosov Moscow State University, Moscow, Russia.
  • Nikitin NA; N.F. Gamaleya National Research Center for Epidemiology and Microbiology, Ministry of Health of the Russian Federation, Moscow, Russia.
  • Karpova OV; Department of Virology, Faculty of Biology, Lomonosov Moscow State University, Moscow, Russia.
Front Microbiol ; 13: 845316, 2022.
Article in English | MEDLINE | ID: covidwho-1798931
ABSTRACT
A recombinant vaccine candidate has been developed based on the major coronaviruses' antigen (S protein) fragments and a novel adjuvant-spherical particles (SPs) formed during tobacco mosaic virus thermal remodeling. The receptor-binding domain and the highly conserved antigenic fragments of the S2 protein subunit were chosen for the design of recombinant coronavirus antigens. The set of three antigens (Co1, CoF, and PE) was developed and used to create a vaccine candidate composed of antigens and SPs (SPs + 3AG). Recognition of SPs + 3AG compositions by commercially available antibodies against spike proteins of SARS-CoV and SARS-CoV-2 was confirmed. The immunogenicity testing of these compositions in a mouse model showed that SPs improved immune response to the CoF and PE antigens. Total IgG titers against both proteins were 9-16 times higher than those to SPs. Neutralizing activity against SARS-CoV-2 in serum samples collected from hamsters immunized with the SPs + 3AG was demonstrated.
Keywords
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Topics: Vaccines Language: English Journal: Front Microbiol Year: 2022 Document Type: Article Affiliation country: Fmicb.2022.845316

Similar

MEDLINE
LILACS
LIS
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Topics: Vaccines Language: English Journal: Front Microbiol Year: 2022 Document Type: Article Affiliation country: Fmicb.2022.845316